Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Why does the Omicron sub-variant spread faster than the original?

22 Feb, 2022 | 09:55h | UTC

Why does the Omicron sub-variant spread faster than the original? – Nature

Related:

Conflicting reports raise questions about whether any monoclonals work against Omicron’s sister variant.

Covid-19: What do we know about omicron sublineages?

We regret to inform you that we are now discussing subvariants – Vox

Sudden rise of more transmissible form of Omicron catches scientists by surprise.

Omicron’s sister variant spreads faster. So why did the one we call Omicron hit first?

[Preprint] Study suggests SARS-CoV-2 Omicron subvariants BA.2 is even more transmissible than the original variant.

BA.2 is like Omicron’s sister. Here’s what we know about it so far – The Conversation

 

[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.

22 Feb, 2022 | 09:58h | UTC

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Children and Adolescents: A Large-Scale Observational Study – Preprints with The Lancet

Commentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical

 

Podcast: Tips and tricks for healing up patients with helicobacter.

22 Feb, 2022 | 08:43h | UTC

Podcast: #322 H. Pylori Infection – The Curbsiders

 

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy.

22 Feb, 2022 | 08:15h | UTC

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy – Current Opinion in Virology

 

ESCMID rapid guidelines for assessment and management of long COVID.

21 Feb, 2022 | 09:31h | UTC

ESCMID rapid guidelines for assessment and management of long COVID – Clinical Microbiology and Infection

Related:

ERS statement on Long COVID-19 follow-up.

Proposed subtypes of long-Covid and their respective potential therapies.

EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.

Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.

Global surveillance, research, and collaboration needed to improve understanding and management of long COVID.

Provocative study suggests that persistent physical symptoms after COVID-19 infection may be associated more with the belief in having been infected with SARS-CoV-2 than with having laboratory-confirmed COVID-19 infection.

Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.

Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.

WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).

Characterizing long COVID: a living systematic review.

Long Covid – The illness narratives.

New guidelines to help doctors manage long COVID patients published.

M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)

 

RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.

21 Feb, 2022 | 09:34h | UTC

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial – JAMA Internal Medicine

Commentaries:

Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN

Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP

Related:

Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.

Long-term consequences of the misuse of ivermectin data.

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.

21 Feb, 2022 | 09:30h | UTC

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus – European Heart Journal

News Release: Review highlights impact of Long COVID on cardiovascular system – University of Oxford

Related:

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 

Perspective | Is it time to live with COVID-19? Some scientists warn of ‘endemic delusion’.

21 Feb, 2022 | 09:28h | UTC

Is it time to live with COVID-19? Some scientists warn of ‘endemic delusion’ – Science

 

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.

21 Feb, 2022 | 09:33h | UTC

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis – International Journal of Infectious Diseases

 

RCT: Single-dose metronidazole vs. treatment for 7 days for treating Trichomonas vaginalis in women.

21 Feb, 2022 | 08:23h | UTC

A Comparison of Single-Dose Versus Multidose Metronidazole by Select Clinical Factors for the Treatment of Trichomonas vaginalis in Women – Sexually Transmitted Diseases (link to abstract – $ for full-text)

 

New U.S. childhood and adolescent immunization schedule released by ACIP.

18 Feb, 2022 | 10:05h | UTC

Recommended Childhood and Adolescent Immunization Schedule: United States, 2022 – Pediatrics

See also:

Child and Adolescent Immunization Schedule: Recommendations for Ages 18 Years or Younger, United States, 2022 – Centers for Disease Control and Prevention

Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2022 – CDC Morbidity and Mortality Weekly Report

 

New U.S. adult immunization schedule released by ACIP.

18 Feb, 2022 | 10:07h | UTC

Recommended Adult Immunization Schedule, United States, 2022 – Annals of Internal Medicine

News release: New adult immunization schedule recommends changes to zoster, pneumococcal, and hep B vaccines – American College of Physicians

See also: Adult Immunization Schedule: Recommendations for Ages 19 Years or Older, United States, 2022 – Centers for Disease Control and Prevention

 

Cohort Study: Risks of mental health outcomes in people with covid-19.

18 Feb, 2022 | 10:02h | UTC

Risks of mental health outcomes in people with covid-19: cohort study – The BMJ

Editorial: Mental health after covid-19 – The BMJ

News release: Study suggests increased risk of mental health disorders after COVID-19 infection – BMJ

Commentaries:

Mental health in people with covid-19 – The BMJ

Large study reveals clearer links between COVID-19, mental health risks – CIDRAP

 

Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.

18 Feb, 2022 | 10:01h | UTC

Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada – JAMA

 

The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.

18 Feb, 2022 | 09:56h | UTC

The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury: State-of-the-Art Review – JACC: Basic to Translational Science

Related: COVID-19 infections increase risk of heart conditions up to a year later, study finds.

 

WHO Interim Guidance: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant.

18 Feb, 2022 | 09:59h | UTC

Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

Opinion | Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2.

18 Feb, 2022 | 09:54h | UTC

Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2 – STAT

 

Perspective: We’re entering the control phase of the pandemic.

18 Feb, 2022 | 08:49h | UTC

We’re Entering the Control Phase of the Pandemic – The Atlantic

 

Dengue infection: Global importance, immunopathology and management.

18 Feb, 2022 | 08:14h | UTC

Dengue infection: Global importance, immunopathology and management – Clinical Medicine Journal

 

Review: Rickettsial illnesses, a leading cause of acute febrile illness.

18 Feb, 2022 | 08:16h | UTC

Rickettsial illnesses, a leading cause of acute febrile illness – Clinical Medicine Journal

 

Leptospirosis: clinical aspects.

18 Feb, 2022 | 08:13h | UTC

Leptospirosis: clinical aspects – Clinical Medicine Journal

 

Review: Emerging tropical neurological infections.

18 Feb, 2022 | 08:12h | UTC

Emerging tropical neurological infections – Clinical Medicine Journal

 

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

17 Feb, 2022 | 10:11h | UTC

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

 

RCT: Oral Nirmatrelvir for high-risk adults with Covid-19 reduces the risk of hospitalization by 89%.

17 Feb, 2022 | 10:14h | UTC

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Audio Interview: A New Antiviral against Covid-19 – new England Journal of Medicine

Related:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

 

Commentary on Twitter

 

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

17 Feb, 2022 | 10:13h | UTC

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 – New England Journal of Medicine

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.